CTIS2024-512102-25-00进行中（未招募）1 期
J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma - JIO-MC-JZHD
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue., Participants must be able to swallow capsules.
排除标准
- •Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant., Participants must not have untreated tumor that has spread to the brain or spinal cord., Participants must not have a serious active disease other than neuroblastoma., Participants must not have a condition affecting absorption., Participants must not have had prior aurora kinase inhibitor exposure., Participants must not have a known allergy to the study treatment., Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
研究者
相似试验
进行中（未招募）
1 期
Alisertib in relapsed or refractory urothelial cancerEUCTR2014-000557-36-ITFondazione IRCCS Istituto Nazionale dei tumori130
已完成
1 期
Alisertib for Acute Myeloid LeukemiaAcute Myelogenous LeukemiaNCT01779843Massachusetts General Hospital22
进行中（未招募）
不适用
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaPlatinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomaMedDRA version: 11.1Level: LLTClassification code 10033131Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10016180Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10052171Term: <Manually entered code. Term in E.1.1>EUCTR2008-006979-72-PLMillennium Pharmaceuticals, Inc56
进行中（未招募）
1 期
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaPlatinum-refractory and platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomaMedDRA version: 11.1Level: LLTClassification code 10033131Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10016180Term: <Manually entered code. Term in E.1.1>MedDRA version: 11.1Level: LLTClassification code 10052171Term: <Manually entered code. Term in E.1.1>EUCTR2008-006979-72-FRMillennium Pharmaceuticals, Inc31
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-BEEli Lilly and Company71